10 Results for "

active conformational state

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "active conformational state" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-160406
CAS No.: 2332803-84-4
SNX281 is a selective STING agonist, with IC50 values of 4.1, 4.5, 10.7, and 3.7 μM against human, mouse, rat, and monkey STING, respectively. SNX281 undergoes homodimerization at the STING binding site, triggering a conformational shift of STING from an inactive open state to an active closed state, thereby driving downstream STING-dependent signaling pathways. SNX281 induces type I interferons, IFN-β, TNF-α, IL-6, cytokine release, T cell responses, and long-lasting immune memory. SNX281 exhibits anti-tumor activity and is applicable to research related to colorectal cancer, melanoma, advanced solid tumors, lymphoma, and ovarian cancer .
loading...
    loading...
Cat. No.: HY-173521
CAS No.: 3026520-19-1
Research Areas:  

Infection

JNJ-9676 is an orally active Coronavirus M protein inhibitor and selective Sarbecovirus inhibitor. JNJ-9676 binds to the M protein dimer and forces the protein into an alternative conformational state with a compound-induced binding pocket. JNJ-9676 demonstrates in vitro nanomolar antiviral activity against SARS-CoV-2, SARS-CoV and Sarbecovirus strains from bat and pangolin zoonotic origin .
loading...
    loading...
Cat. No.: HY-177425
CAS No.: 152674-95-8
Target:  

Cannabinoid Receptor

Research Areas:  

Metabolic Disease

AM11542 is a cannabinoid receptor 1 (CB1) agonist with a human CB1 Ki of 0.11 nM. AM11542 stabilizes the active conformational state of the CB1 receptor. AM11542 can be used for the research of obesity .
loading...
    loading...
Cat. No.: HY-186310
Research Areas:  

Neurological Disease

ISRACT-02 is a eIF2B modulator. The Kd values of ISRACT-02 for eIF2B WT and eIF2B Δ-latch are 174 nM and 385 nM, respectively. Depending on the conformation of its amide bond (trans or cis), ISRACT-02 binds to and stabilizes the inactive conformation (I-state) or active conformation (A-state) of eIF2B, respectively. ISRACT-02 can be used in studies related to leukodystrophy, Alzheimer's disease, traumatic brain injury, and Down syndrome .
loading...
    loading...
Cat. No.: HY-Z20873
CAS No.: 84210-35-5
Target:  

Parasite

Research Areas:  

Infection

MK-4815 is an orally active small-molecule allosteric inhibitor of Falcilysin (FLN) with antimalarial activity. MK-4815 inhibits the viability of Plasmodium falciparum NF54 and Dd2 strains with IC50 values of 38 and 40 ng/mL, respectively. MK-4815 preferentially accumulates in erythrocytes containing mature trophozoite/schizont-stage parasites. MK-4815 preferentially binds to the partially closed conformation of FLN, shifting the FLN conformational equilibrium toward the partially closed state and restricting the hinge region-mediated transition from the partially closed state to the open state, thereby interfering with the catalytic cycle of FLN. MK-4815 can be used for malaria-related research .
loading...
    loading...
Cat. No.: HY-189244
CAS No.: 3103996-88-6
Target:  

RSV

Research Areas:  

Infection

RSV-IN-14 is an orally active pre-fusion F protein inhibitor of respiratory syncytial virus (RSV), with a Kd of 5.0 μM, and exhibits lung-targeted distribution properties. RSV-IN-14 binds to the central cavity of the trimeric pre-fusion F protein, locks it in the pre-fusion state, and inhibits the conformational changes required for membrane fusion to block viral entry. RSV-IN-14 suppresses respiratory syncytial virus-induced syncytium formation. RSV-IN-14 can be used in studies on respiratory syncytial virus infection .
loading...
    loading...
Cat. No.: HY-P991964
Synonyms: Rendomab-B49

Target:  

Endothelin Receptor

Research Areas:  

Cancer

Rendomab B4 (Rendomab-B49) is a monoclonal antibody targeting ETB. Rendomab B4 preferentially binds to ETB in the active conformational state and exhibits selectivity for ETB on melanoma cells. Rendomab B4 inhibits the G protein-dependent phospholipase C (PLC) pathway, blocks ET-3-induced Gαi/o-mediated inhibition of adenylate cyclase, and does not affect the activation of the ERK1/2 pathway. Rendomab B4 is applicable to melanoma-related research .
loading...
    loading...
Cat. No.: HY-P1609
CAS No.: 105116-61-8
Target:  

Renin Enteropeptidase

Research Areas:  

Cardiovascular Disease

CP-69799 is an azahomostatine-containing oligopeptide transition-state analogue inhibitor with a hog renin IC50 of 6e-9 M, human plasma renin IC50 of 3e-7 M and Ki of 0.310 μM, and endothiapepsin Ki of 0.27 μM. CP-69799 binds endothiapepsin’s active site cleft in extended conformation, fills S4 to S3' pockets, displaces native solvent molecules, induces domain rotation, and reduces thermal mobility of endothiapepsin’s flap and helix regions. CP-69799 acts as a transition-state analogue inhibitor of hog renin and human plasma renin. CP-69799 contains a polar lysine residue at the P2' position, with a nitrogen atom replacing the P1' Cα atom of the hydroxyethylene dipeptide isostere. CP-69799 can be used for the research of hypertension .
loading...
    loading...
Cat. No.: HY-19896A
CAS No.: 1204956-74-0
COTI-2 hydrochloride is an orally active thiosemicarbazone anticancer agent and p53 mutant activator. COTI-2 hydrochloride induces Apoptosis. COTI-2 hydrochloride triggers the activation of AMPK and the inhibition of the mTOR pathway. COTI-2 hydrochloride induces DNA damage and replication stress responses. COTI-2 hydrochloride binds to misfolded mutant p53 proteins, thereby inducing conformational changes that restore p53 to its normal state and reactivate its function. COTI-2 hydrochloride acts on a variety of cancer cell lines and xenografts. COTI-2 hydrochloride can be used in research related to colorectal cancer, small cell lung cancer, glioblastoma, breast cancer, and ovarian cancer .
loading...
    loading...
Cat. No.: HY-184501
CAS No.: 486440-74-8
Research Areas:  

Cancer

UE01 is an orally active, selective small-molecule modulator targeting both ULK1/ERK1/2. UE01 activates hULK1 with an EC50 of 695.30 nM and a KD of 114.3 nM for ULK1; it inhibits hERK1 with an IC50 of 179.90 nM and a KD of 114 nM for ERK1; it shows weak binding to ERK2 with a KD of 2.8 mM. UE01 induces the conformational transition of ULK1 from an inactive to an active state, enhances the phosphorylation of ULK1 Ser317 and mAtg13 Ser355, and reduces the phosphorylation of ULK1 Ser757. UE01 competitively occupies the ATP-binding pocket of ERK1, inhibits ERK1 kinase activity, and reduces the activity of the ERK1/2 signaling pathway. UE01 induces complete autophagy flux and apoptosis, upregulates Atg5, Atg7, LC3-II/LC3-I, Bax, cytochrome C (Cyt c), Cleaved-Caspase 3, Cleaved-PARP1 and E-cadherin, downregulates p62, Bcl-2, MMP-2 and MMP-9, reduces the phosphorylation of Exo70 Ser250, and promotes the proteasome-dependent degradation of Cav-1, thereby inhibiting EMT-related phenotypes and extracellular matrix degradation. UE01 can be used in studies related to triple-negative breast cancer .
loading...
    loading...